Delving into the Latest Updates on 8 HLA-A2 restricted peptides Vaccine(Ludwig Institute for Cancer Research) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Melanoma, Cutaneous MalignantNeoplasms

Originator Organization

Ludwig Institute for Cancer Research Ltd.

Active Organization-

Inactive Organization

Ludwig Institute for Cancer Research Ltd.

License Organization-

Drug Highest PhaseDiscontinuedPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This cancer vaccine research study involves the injection of the NY-ESO-1b peptide along with 2 other agents to help stimulate the immune system. Peptides are small fragments of protein. NY- ESO-1 peptides are normally found in the testis and the placenta. They have also been found on various types of cancer cells. The purpose is to stimulate the immune system to react against the peptides that are found on cancer cells.

Start Date03 Sep 2003

Sponsor / Collaborator

Ludwig Institute for Cancer Research Ltd.

100 Clinical Results associated with 8 HLA-A2 restricted peptides Vaccine(Ludwig Institute for Cancer Research)

Login to view more data

100 Translational Medicine associated with 8 HLA-A2 restricted peptides Vaccine(Ludwig Institute for Cancer Research)

Login to view more data

100 Patents (Medical) associated with 8 HLA-A2 restricted peptides Vaccine(Ludwig Institute for Cancer Research)

Login to view more data

100 Deals associated with 8 HLA-A2 restricted peptides Vaccine(Ludwig Institute for Cancer Research)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Melanoma, Cutaneous Malignant	Phase 2	Belgium	Ludwig Institute for Cancer Research Ltd.	01 Jan 2005
Neoplasms	Phase 1	Germany	Ludwig Institute for Cancer Research Ltd.	03 Sep 2003

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00145158 (CTgov)	Phase 1/2	Melanoma, Cutaneous Malignant	23	CpG 7909 (Cohort 1: 8 HLA-A2-restricted Peptides and CpG 7909)	nricpsdoeg = nyciuwjoey ikizfjggyi (vpuycfgfwm, yklaqvzmly - rsvqiabqxi) View more	-	07 Apr 2022
NCT00145158 (CTgov)	Phase 1/2	Melanoma, Cutaneous Malignant	23	8 HLA-A2-restricted peptides and Montanide ISA51 (Cohort 2: 8 HLA-A2-Restricted Peptides and Montanide ISA51)	nricpsdoeg = xkpmujmjhu ikizfjggyi (vpuycfgfwm, krnqomhrla - pkgpirphtv) View more	-	07 Apr 2022
NCT00199836 (CTgov)	Phase 1	Neoplasms	14	NY-ESO-1b peptide plus CpG 7909 and Montanide® ISA-51	votkznuswh = bqvzkbwnnx ngpfvayqty (bdcyeuwpdm, wzahueyjtz - ejpbizbqwv) View more	-	15 Jul 2021